Celularity, Inc. (NASDAQ:CELU) Short Interest Down 54.3% in September

Celularity, Inc. (NASDAQ:CELU) was the target of a significant decrease in short interest in the month of September. As of September 30th, there was short interest totaling 640,100 shares, a decrease of 54.3% from the September 15th total of 1,400,000 shares. Currently, 4.3% of the company’s stock are short sold. Based on an average daily volume of 278,900 shares, the days-to-cover ratio is presently 2.3 days. Based on an average daily volume of 278,900 shares, the days-to-cover ratio is presently 2.3 days. Currently, 4.3% of the company’s stock are short sold.

Institutional Trading of Celularity

A number of hedge funds and other institutional investors have recently modified their holdings of CELU. Valmark Advisers Inc. purchased a new stake in shares of Celularity in the second quarter worth $98,000. Bank of America Corp DE increased its stake in shares of Celularity by 1,538.1% in the second quarter. Bank of America Corp DE now owns 37,300 shares of the company’s stock worth $73,000 after purchasing an additional 35,023 shares in the last quarter. Acadian Asset Management LLC purchased a new position in Celularity during the first quarter valued at $34,000. Finally, XTX Topco Ltd grew its stake in Celularity by 106.4% during the second quarter. XTX Topco Ltd now owns 21,452 shares of the company’s stock valued at $42,000 after acquiring an additional 11,057 shares in the last quarter. 19.02% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

CELU has been the topic of a number of recent research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Celularity in a report on Wednesday, October 8th. WBB Securities upgraded shares of Celularity from a “hold” rating to a “buy” rating and set a $6.00 price objective on the stock in a report on Tuesday, September 9th. Finally, Wall Street Zen cut shares of Celularity from a “hold” rating to a “sell” rating in a report on Friday, September 5th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $6.00.

Celularity Stock Up 1.0%

Shares of Celularity stock opened at $2.02 on Wednesday. The company has a market cap of $53.91 million, a price-to-earnings ratio of -0.64 and a beta of 0.75. The company’s 50 day moving average is $2.62 and its 200 day moving average is $2.30. Celularity has a twelve month low of $1.00 and a twelve month high of $5.22.

Celularity (NASDAQ:CELU) last issued its quarterly earnings data on Friday, August 29th. The company reported ($1.02) earnings per share for the quarter. Celularity had a negative net margin of 165.22% and a negative return on equity of 459.57%. The company had revenue of $5.74 million for the quarter.

Celularity Company Profile

Celularity Inc, a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease.